2023-10-15 00:30:28
Danish medical registry reveals results of analysis of 1.98 million patients
Entered 2023.10.15 09:30 Views 8 Entered 2023.10.15 09:30 Views 8
[사진=클립아트코리아]
A risk of dementia has been identified with PPI (proton pump inhibitor), one of the many prescription drugs for gastrointestinal diseases.
The latest research results showed that the risk of dementia significantly increased in people taking PPIs. In particular, those who took this drug before the age of 70 had the highest risk of dementia.
A large-scale cohort analysis study conducted by Dr. Nelsan Furhadi, Department of Neurology, Copenhagen University Hospital, League Hospital, Denmark, was published in an international academic journal. <알츠하이머&치매(Alzheimer’s and Dementia)> It was published online on October 5, 2023.
The study analyzed 1,983,785 patient data between 60 and 75 years old registered in the Danish Medical Information Registry between 2000 and 2018. Most of them reported their experience using PPIs. The study was followed up for a total of 10.3 years (median).
What is noteworthy is that 21.2% of these patients diagnosed with dementia had a history of taking PPI. In the control group who were not diagnosed with dementia, the rate was somewhat lower at 18.9%. As a result, the risk of developing dementia from all causes before the age of 90 was highest in those aged 60 to 69 who took PPI at 36%, and 6% in those aged 80 to 89.
The research team said in the report, “Regardless of when PPI treatment was started, we found that taking PPI before the age of 90 significantly increased the risk of dementia,” adding, “This association was found to be higher in younger dementia cases. “PPI use in middle age may be an important factor that has a greater impact on dementia risk than use in later life.”
However, he added, “This study omitted data such as the period of PPI use, PPI of over-the-counter medicine ingredients, and the number of people who used intravenous PPI in hospitals, so there are some limitations in the interpretation of the results.”
Meanwhile, the gastrointestinal medicine market showed significant growth in 2019, with PPI prescriptions being pointed out as substitutes due to the detection of the impurity N-nitrosodimethylamine (NDMA) in gastrointestinal medicines containing ranitidine.
As ranitidine was withdrawn from the gastrointestinal medicine market, a large number of prescriptions switched to PPI preparations. In fact, according to UBIST, the total prescription amount for the top 10 PPI products increased by 10.6% from 208.9 billion won in 2018 to 231.1 billion won in 2020.
1697333599
#risk #dementia #stomach #medicine #PPI #long #time
